These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J; Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R J Clin Oncol; 2003 Jan; 21(1):16-9. PubMed ID: 12506164 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. Rajkumar SV Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892 [TBL] [Abstract][Full Text] [Related]
5. The future role of thalidomide in multiple myeloma. Boccadoro M; Blade J; Attal M; Palumbo A Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768 [TBL] [Abstract][Full Text] [Related]
8. Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Leuk Lymphoma; 2003 Nov; 44(11):1943-6. PubMed ID: 14738147 [TBL] [Abstract][Full Text] [Related]
9. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR; J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178 [TBL] [Abstract][Full Text] [Related]
10. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA Med Oncol; 2002; 19(4):219-26. PubMed ID: 12512915 [TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968 [TBL] [Abstract][Full Text] [Related]
12. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508 [TBL] [Abstract][Full Text] [Related]
14. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M Haematologica; 2004 Jul; 89(7):826-31. PubMed ID: 15257934 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870 [TBL] [Abstract][Full Text] [Related]